Shah Smital
SEC CIK 1808821 · EDGAR
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| LENZ | LENZ Therapeutics, Inc. | Dir | 5,882 | $100.0K | — | 1 | 2021-06-29 | 2021-06-29 |
Most active insiders at LENZ, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Versant Vantage II GP-GP, LLC | 10% | — | $10.35M |
| 2 | Olsson Shawn | Chief Commercial Off | — | $261.0K |
| 3 | Schimmelpennink Evert B. | Pres, CEO, Sec, Dir | $251.4K | — |
| 4 | MCCOLLUM JAMES W | Dir | $239.3K | — |
| 5 | Chevallard Daniel R. | CFO | $114.3K | — |
| 6 | George Jeffrey P. | Dir | $49.9K | — |
Shah Smital made no open-market trades at LENZ in the last 12 months.
Transactions 1
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2021-07-01 | 2021-06-29 | LENZ | LENZ Therapeutics, Inc. | Shah Smital | Dir | P - Purchase | $17.00 | +5,882 | 5,882 | New | +$100.0K |
Purchase Sale Sale after option exercise All abbreviations